Literature DB >> 26390517

Comparison of neointimal coverage between everolimus-eluting stents and sirolimus-eluting stents: an optical coherence tomography substudy of the RESET (Randomized Evaluation of Sirolimus-eluting versus Everolimus-eluting stent Trial).

Takashi Kubo1, Takashi Akasaka, Ken Kozuma, Kazuo Kimura, Masaki Kawamura, Tetsuya Sumiyoshi, Yasushi Ino, Yoshihiro Morino, Kengo Tanabe, Kazushige Kadota, Takeshi Kimura.   

Abstract

AIMS: The aim of the present study was to compare vascular healing response between the first-generation sirolimus-eluting stent (SES) and the second-generation everolimus-eluting stent (EES) by using optical coherence tomography (OCT). METHODS AND
RESULTS: The RESET was a prospective, multicentre, randomised, open-label trial comparing EES and SES. Of the 3,197 patients enrolled in the RESET, nine-month follow-up OCT after stent implantation was performed in 100 patients (48 EES-treated lesions in 44 patients and 62 SES-treated lesions in 56 patients), thus constituting the OCT substudy population. The percentage of uncovered struts per lesion (8±15% vs. 14±19%, p=0.031) and cross-sections with >30% uncovered struts per lesion (6±14% vs. 18±29%, p=0.009) was significantly lower in EES compared with SES. The frequency of DES-treated lesions with incomplete stent apposition (8 [17%] vs. 29 [47%], p<0.001) was significantly lower in EES compared with SES. Intra-stent thrombus was comparably observed between EES and SES (1 [2%] vs. 5 [8%], p=0.229).
CONCLUSIONS: Compared with SES, EES was associated with a favourable vascular response at nine months after stent implantation.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26390517     DOI: 10.4244/EIJV11I5A109

Source DB:  PubMed          Journal:  EuroIntervention        ISSN: 1774-024X            Impact factor:   6.534


  5 in total

1.  Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing.

Authors:  Sho Torii; Hiroyuki Jinnouchi; Atsushi Sakamoto; Hiroyoshi Mori; Joohyung Park; Falone C Amoa; Mariem Sawan; Yu Sato; Anne Cornelissen; Salome H Kuntz; Matthew Kutyna; Ka Hyun Paek; Raquel Fernandez; Ryan Braumann; Eric K Mont; Dipti Surve; Maria E Romero; Frank D Kolodgie; Renu Virmani; Aloke V Finn
Journal:  Eur Heart J       Date:  2020-02-01       Impact factor: 29.983

2.  Effect of Rivaroxaban and Clopidogrel Combination Therapy on In-Stent Responses After Everolimus-Eluting Stent Implantation in a Porcine Coronary Model.

Authors:  Daisuke Kitano; Suguru Migita; Yuxin Li; Rie Takahashi; Yoshiki Taniguchi; Takafumi Kurosawa; Mitsumasa Sudo; Hironori Haruta; Takafumi Hiro; Tadateru Takayama; Masako Mitsumata; Taro Matsumoto; Yasuo Okumura; Atsushi Hirayama
Journal:  J Atheroscler Thromb       Date:  2020-11-18       Impact factor: 4.928

3.  Randomised trial of the comparison of drug-eluting stents in patients with diabetes: OCT DES trial.

Authors:  Stephen Hamshere; Alex Byrne; Tawfiq Choudhury; Sean M Gallagher; Krishnaraj S Rathod; Julia Lungley; Charles J Knight; Akhil Kapur; Daniel A Jones; Anthony Mathur
Journal:  Open Heart       Date:  2018-04-05

4.  Comparative assessment of three drug eluting stents with different platforms but with the same biodegradable polymer and the drug based on quantitative coronary angiography and optical coherence tomography at 12-month follow-up.

Authors:  Robert J Gil; Jacek Bil; Jacek Legutko; Tomasz Pawłowski; Katarzyna E Gil; Dariusz Dudek; Ricardo A Costa
Journal:  Int J Cardiovasc Imaging       Date:  2017-09-30       Impact factor: 2.357

5.  Comparison of neointimal coverage between ultrathin biodegradable polymer-coated sirolimus-eluting stents and durable polymer-coated everolimus-eluting stents: 6 months optical coherence tomography follow-up from the TAXCO study.

Authors:  Atul Abhyankar; Alexandre Abizaid; Daniel Chamié; Mihir Rathod
Journal:  Catheter Cardiovasc Interv       Date:  2020-04-03       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.